Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01580696 · ClinicalTrials.gov registry record · Phase 1
Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
A Phase 1 study, sponsored by COL George Peoples, MD, FACS.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT01580696: Completed Phase 1 study, sponsored by COL George Peoples, MD, FACS.
NCT01580696 is a Phase 1 study that has completed, run by COL George Peoples, MD, FACS. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01580696, a Phase 1 study, has completed, sponsored by COL George Peoples, MD, FACS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
Folate binding protein (FBP) is highly over-expressed in breast, ovarian and endometrial cancers and is the source of immunogenic peptides (E39) that can stimulate cytotoxic T lymphocytes (CTL) to recognize and destroy FBP-expressing cancer cells in the laboratory. The purpose of this study is to test whether a peptide-based vaccine consisting of the E39 peptide mixed with the FDA-approved immunoadjuvant granulocyte macrophage colony-stimulating factor (GM-CSF) is safe and effective at inducing an in vivo peptide-specific immune response. Furthermore, the investigators intend to determine the best dose of the vaccine to utilize to produce this immunity most efficiently. The investigators will determine whether immunity to FBP will prevent clinical recurrence. Additionally, the investigators will compare these results with results from a trial utilizing the E75 peptide (from the HER2/neu protein) in ovarian and endometrial cancer patients in preparation for studying a combination vaccine.
Interventions
- BIOLOGICAL E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster
- OTHER Non-vaccine clinically matched control group
- BIOLOGICAL E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster
- BIOLOGICAL E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster
- BIOLOGICAL E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2012-04 |
| Est. Completion | 2016-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01580696
The ClinicalTrials.gov registry entry for NCT01580696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is COL George Peoples, MD, FACS, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster is the first listed.
NCT01580696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01580696 about?
NCT01580696 is a clinical study titled "Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer". Folate binding protein (FBP) is highly over-expressed in breast, ovarian and endometrial cancers and is the source of immunogenic peptides (E39) that can stimulate cytotoxic T lymphocytes (CTL) to recognize and destroy FBP-expressing cancer cells in the laboratory. The purpose of this study is to te...
What is the current status of trial NCT01580696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2012-04. Estimated completion is 2016-07-31.
What interventions are being tested in trial NCT01580696?
The interventions under investigation include: E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster (BIOLOGICAL), Non-vaccine clinically matched control group (OTHER), E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster (BIOLOGICAL), E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster (BIOLOGICAL), E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster (BIOLOGICAL).
Who is sponsoring clinical trial NCT01580696?
This trial is sponsored by COL George Peoples, MD, FACS, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.